| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
As a leading franchise brokerage firm in the USA and Canada, Klimate Group is renowned for its exceptional reputation in the industry. Specializing in connecting aspiring entrepreneurs with top franchise opportunities, Klimate Group stands out for its extensive network of franchisors, personalized guidance for franchisees, and commitment to fostering successful partnerships. With a track record of matching individuals with franchises that align with their goals and values, Klimate Group has established itself as a trusted and innovative player in the franchising world, setting the standard for excellence and professionalism.
Bigelow is the M + A Advisor exclusively for owners of high-performing private companies — Entrepreneur Owner-Managers with their skin in the game. Our scrappy boutique firm behaves as one collaborative team. Leveraging our independence and exclusive EOM focus, we have helped hundreds of clients build and capture Enterprise Value while respecting their values, their legacy and the intersection of their professional and personal goals. Frequently our work with clients goes on for years in advance of a wealth-building transaction. Unlike virtually all of the firms with which we compete, we are independently owned. We have only one source of revenue — our Entrepreneur Owner-Manager clients. No referral fees. No investing, trading, lending, or underwriting. No buy-side advisory. No products to sell. No conflicts. We aspire to be completely aligned with achieving our clients potential, striving endlessly to be masters of our craft.
Precision AQ is a global life science commercialization vendor that specializes in Health Economics and Outcomes Research (HEOR), pricing, and market access consulting for pharmaceutical and biotech companies. Headquartered in New York City, the company operates with a strong emphasis on remote work. Precision AQ is dedicated to transforming patient lives by improving access to life-changing therapies through innovative strategies and data-driven approaches. The company offers a wide range of services to support clients throughout the healthcare journey. These include research, strategy, and product development, as well as marketing, branding, and public relations. Precision AQ also focuses on generating evidence for HEOR, optimizing payer access, and facilitating investor relations. Their expertise helps clients navigate the complexities of the market and enhance their presence among healthcare professionals and patients.